Download PDF
Hamostaseologie 1997; 17(01): 43-48
DOI: 10.1055/s-0038-1660012
New antithrombotische Medikamente
Schattauer GmbH

New Platelet Aggregation Inhibitors

J. Vermylen
,
R. Verhaeghe
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • REFERENCES

  • 1 Boneu B. on behalf of the study investigators. Clopidogrel dose-ranging phase II-study in patients with atherosclerotic disease. J Am Coll Cardiol 1996; 27: 132A-133A (abstract)
    PubMedGoogle Scholar
  • 2 Herbert JM, Frehel D, Vallee E. et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-98.
    CrossrefPubMedGoogle Scholar
  • 3 Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drugs Ther 1992; 6: 29-33.
    CrossrefPubMedGoogle Scholar
  • 4 Savage MP, Goldberg S, Bove AA. et al. for the M-HEART II Study Group. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92: 3194-200.
    CrossrefPubMedGoogle Scholar
  • 5 Collen D, Masuda M, Lu HR. et al. Effect of ridogrel, a combined thromboxane A2 synthase inhibitor/prostaglandin endoperoxide receptor antagonist, on the lysis of platelet rich coronary arterial thrombi with recombinant tissue-plasminogen activator in a canine model. Fibrinolysis 1992; 6: 7-15.
    PubMedGoogle Scholar
  • 6 Hoet B, Arnout J, Van Geet C. et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma β-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemost 1990; 64: 87-90.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 The RAPT Investigators.. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The ridogrel versus aspirin trial (RAPT). Circulation 1994; 89: 588-95.
    CrossrefPubMedGoogle Scholar
  • 8 Gresele P, Deckmyn H, Arnout J. et al. Characterization of N,N’-bis(3-picolyl)-4-methoxyisophtalamide (picotamide) as a dual thromboxane synthase inhibitor/throm-boxane A2 receptor antagonist in human platelets. Thromb Haemost 1989; 61: 479-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Plow EF, Ginsberg MH. Cellular adhesion: GP Ilb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1988; 9: 117-56.
    PubMedGoogle Scholar
  • 10 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein Ilb-IIIa (integrin αllbβ3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 11300-6.
    PubMedGoogle Scholar
  • 11 Peerlinck K, Delepeleire I, Goldberg M. et al. MK-383 – a selective, non-peptide platelet glycoprotein Ilb/IIIa receptor antagonist active in man. Circulation 1993; 88: 1512-7.
    CrossrefPubMedGoogle Scholar
  • 12 Collen D, Lu HR, Stassen JM. et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GP Ilb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994; 71: 95-102.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Kleiman NS, Ohman EM, Califf RM. et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
    CrossrefPubMedGoogle Scholar
  • 14 Tcheng JE, Ellis SG, George BS. et al. Pharmacodynamics of chimeric glycoprotein lib/ Ilia integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation 1994; 90: 1757-64.
    CrossrefPubMedGoogle Scholar
  • 15 The EPIC investigators.. Use of monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
    CrossrefPubMedGoogle Scholar
  • 16 Topol EJ, Califf RM, Weisman HF. et al. on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
    CrossrefPubMedGoogle Scholar
  • 17 Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein Ilb/IIIa inhibitors. Am Heart J 1995; 130: 666-72.
    CrossrefPubMedGoogle Scholar
  • 18 Lefkovits J, Ivanhoe RJ, Califf RM. et al. for the EPIC Investigators. Effects of platelet glycoprotein Ilb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: 1045-51.
    CrossrefPubMedGoogle Scholar
  • 19 Simoons ML, den Boer MJ, van den Brand MJBM. et al. and the European Cooperative Study Group. Randomized trial of a GPIIb/ Ilia platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
    CrossrefPubMedGoogle Scholar
  • 20 Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J 1995; 130: 673-9.
    CrossrefPubMedGoogle Scholar
  • 21 Lincoff AM, Tcheng JE, Bass TA. et al. A multicenter, randomized, double-blind pilot trial of a standard versus low-dose weight, adjusted heparin in patients treated with the platelet GPIIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. J Am Coll Cardiol 1995; 25: 80A-81A (abstract)
    PubMedGoogle Scholar
  • 22 Harrington RA, Kleiman NS, Kottke-Marchant K. et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein Ilb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-7.
    CrossrefPubMedGoogle Scholar
  • 23 Tcheng JE, Harrington RA, Kottke-Mar-chant K. et al. for the Impact Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein Ilb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995; 91: 2151-7.
    CrossrefPubMedGoogle Scholar
  • 24 Tcheng JE, Lincoff AM, Sigmon KN. et al. for the Impact II Investigators. Platelet glycoprotein Ilb/IIIa inhibition with integrelin during percutaneous coronary intervention:the IMPACT II trial. Circulation 1995; 2 Suppl 1: 1-543 abstract
    PubMedGoogle Scholar
  • 25 Bergelson BA, Davidson CJ, Hafley G. et al. for the Impact II Investigators. Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II trial. J Am Coll Cardiol 1996; 27: 83A (abstract)
    PubMedGoogle Scholar
  • 26 Barrett JS, Murphy MG, Peerlinck K. et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein Ilb/IIIa receptor antagonist in healthy men. Clin Pharmacol Ther 1994; 56: 377-88.
    CrossrefPubMedGoogle Scholar
  • 27 Lynch JJ, Cook JJ, Sitko GR. et al. Non-peptide glycoprotein Ilb/IIIA inhibitors. 5 Antithrombotic effects of MK-383. J Pharmacol Exp Ther 1995; 272: 20-32.
    PubMedGoogle Scholar
  • 28 Kereiakes DJ, Kleiman NS, Ambrose J. et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet Ilb/IIIa blockade in high risk patients undergoing cornary angioplasty. J Am Coll Cardiol 1996; 27: 536-42.
    CrossrefPubMedGoogle Scholar
  • 29 Kottke-Marchant K, Simpfendorfer C, Lowrie M. et al. Sustained but variable inhibition of platelet aggregation with xem-lofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 1995; 92 (Suppl. 01) 1-488 (abstract).
    CrossrefPubMedGoogle Scholar
  • 30 Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GPIIb/IIIa receptor blockade: a pilot study of xemlofiban, an orally active antagonist in unstable angina patients eligible for PTCA. J Am Coll Cardiol 1996; 27: 242A (abstract)
    PubMedGoogle Scholar
  • 31 Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
    CrossrefPubMedGoogle Scholar
  • 32 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-6.
    CrossrefPubMedGoogle Scholar
  • 33 Choi ET, Engel L, Callow AD. et al. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist G-pen GRGDSPCA. J Vase Surg 1994; 19: 125-34.
    CrossrefPubMedGoogle Scholar